Cystic Fibrosis Foundation issued the following clinical trial alert in the month of August.
August 7, 2019
Description: This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.
Age: 12 Years and Older
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: No FEV1 Limit
Number of Visits: 6
Length of Participation: 2 years
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04038047